Stocks股票 / Health Care / IART
IART US listed · USD美股 · 美元
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery.Integra LifeSciences Holdings Corporation是一家全球医疗设备制造公司,总部位于新泽西州普林斯顿,成立于1989年,生产用于皮肤再生、神经外科、重建和普通外科的产品。
Company news公司新闻
The latest reporting最新报道
One story, with the reporting behind it.将同一事件汇总,保留各来源报道。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-10-26Earnings财务业绩
next report下次财报 2026-10-29Estimates being cut预期下调
Beat expectations 4 quarters in a row连续 4 季度超预期
Post-earnings drift: -8.5% (20d)财报后漂移:-8.5%(20日)
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 19.8%
Valuation估值
Looks cheap vs sector相对行业偏便宜| Multiple指标 | IART | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/B市净率 | 0.89x | 3.57 | |
| P/S市销率 | 0.57x | 3.19 | |
| Earnings yield盈利收益率 | -55.71% | 2.37 | |
| FCF yield自由现金流收益率 | -3.35% | 3.88 | |
| Shareholder yield股东收益率 | 0.02% | 1.83 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Debt coming due到期债务
FY2025 10-KIn the 12-month bucket following fiscal period end 2025-12-31, it reported $38.8M due — about 5% of its disclosed principal.在财年期末 2025-12-31 之后12个月的区间内,已披露到期本金为 $38.8M,约占其披露本金的 5%。
All maturity buckets are measured from fiscal period end 2025-12-31, not from today.所有到期区间均从财年期末 2025-12-31 起算,而非从今天起算。
Cash reported at 2025-12-31: $235048000.截至 2025-12-31 披露的现金:$235048000。 At the cash-burn pace reported over 2025-01-01 to 2025-12-31, that cash represented about 90.8 months. This scenario excludes debt payments and future financing.按 2025-01-01 至 2025-12-31 期间披露的现金消耗速度,该现金约对应 90.8 个月。此情景不包括债务偿还与未来融资。
Capital-need coverage is partial; incomplete or incompatible filing inputs are not combined.资本需求覆盖信息不完整;不会合并不完整或不兼容的报告数据。
Any available cash-flow scenario is context only. Missing or incompatible inputs are not replaced with zero or a financing forecast.可用现金流情景仅供参考;缺失或不兼容的输入不以零值或融资预测替代。
Sources and cash-flow calculation来源与现金流计算
Figures are XBRL facts from one filing — no two years are mixed. Filing数据取自同一份文件中的 XBRL 事实,不跨文件拼接。文件
0000917520-26-000011, period ending报告期截至 2025-12-31, unit单位 USD.
Cache acquired缓存获取时间: 2026-09-26T08:03:26.594514+00:00.
3/6 buckets reported.个区间有披露。
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwoLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive— absent
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0000917520-26-000011 · Filed提交日期 2026-02-26.
Cache acquired缓存获取时间: 2026-09-26T08:03:26.594514+00:00 · Evaluated as of评估截至 2026-10-26.
- Reported operating cash flow已披露经营活动现金流: $50384000
- Reported equipment spending (capex outflow)已披露设备支出(资本开支流出): $81436000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流(经营现金流减资本开支): $-31052000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变,不包括债务偿还、受限现金调整与未来融资。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Signal history信号历史
engine events引擎事件Company profile公司档案
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery.Integra LifeSciences Holdings Corporation是一家全球医疗设备制造公司,总部位于新泽西州普林斯顿,成立于1989年,生产用于皮肤再生、神经外科、重建和普通外科的产品。
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| Price / Book市净率 | 0.9× | 3.6× | 97% |
| Price / Sales市销率 | 0.6× | 3.2× | 90% |
| Earnings yield盈利收益率 | -55.7% | 2.4% | 3% |
| Free-cash-flow yield自由现金流收益率 | 5.4% | 5.2% | 56% |
| Shareholder yield股东综合回报率 | 0.0% | 1.8% | 12% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -9.8% | -0.4% |
| 1 Month近1月 | -23.3% | -1.0% |
| 3 Months近3月 | -39.8% | +3.1% |
| 6 Months近6月 | +12.7% | +7.0% |
| Year to date年初至今 | -0.8% | +12.1% |
| 1 Year近1年 | -25.0% | +14.4% |
| 3 Years近3年 | -68.0% | +86.0% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $1.4B | $1.5B | $1.6B | $1.5B | $1.6B | $1.6B |
| EPS每股收益 | $1.57 | $1.98 | $2.16 | $0.84 | $-0.09 | $-6.74 |
| Free cash flow自由现金流 | $165M | $264M | $222M | $73M | $25M | $-31M |
| Gross margin毛利率 | 62.0% | 61.2% | 62.3% | 57.4% | 54.8% | 50.9% |
| Net margin净利率 | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| FCF margin自由现金流利润率 | 12.0% | 17.1% | 14.3% | 4.7% | 1.6% | -1.9% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: earnings cash-backed盈利质量:盈利有现金支撑
- Working capital: inventory +59% vs sales +19% — inventory building, demand risk营运资本:存货 +59% 对销售 +19%——存货积压,需求风险
- Pricing power: gross margin −11.1pts over 6 years定价能力:毛利率 6 年下降 11.1 个百分点
- Capital discipline: investment near the peer median资本纪律:投资力度接近同业中位
- Balance sheet: Altman Z 0.62 — distress zone资产负债表:Altman Z 0.62——困境区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $0.56 | $0.48 | +16.7% |
| Mar 2026 | $0.54 | $0.41 | +31.7% |
| Dec 2025 | $0.83 | $0.79 | +5.1% |
| Sep 2025 | $0.54 | $0.43 | +25.6% |
Estimate revisions预期修正
Insiders & shorts内部人与空头
Recent fund flows近期基金流向
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 33% | -7.8% | 3 |
| Feb2月 | 33% | -7.1% | 3 |
| Mar3月 | 0% | -4.6% | 3 |
| Apr4月 | 33% | -18.7% | 3 |
| May5月 | 67% | +8.7% | 3 |
| Jun6月 | 33% | -2.3% | 3 |
| Jul7月 | 33% | -5.1% | 3 |
| Aug8月 | 67% | +2.2% | 3 |
| Sep9月 | 0% | -3.2% | 4 |
| Oct10月 | 25% | -5.7% | 4 |
| Nov11月 | 100% | +10.0% | 3 |
| Dec12月 | 33% | -5.0% | 3 |